Peptide cycle timelines: what the science says vs. TikTok

What did @ttoth27 actually say?

The creator rattled off cycling protocols for about eight different peptides and compounds, including MOTS-c, BPC-157, NAD+, GHK-Cu, and others. The core argument was straightforward: these compounds "help signal natural occurring processes in the body," and you shouldn't keep those signals "in overdrive 365 days a year." The framing was that cycling protects you from health consequences. That's a reasonable premise. The problem is that the specific timelines, four weeks on, four weeks off, twelve months straight, six weeks as needed, were delivered as if they came from established clinical protocols. They did not. Most of these are derived from anecdotal bodybuilding communities and informal online consensus, not randomized controlled trials.

It's worth noting that the creator appears to mispronounce or misname several compounds. "Samax" is almost certainly Semax, and "CB500" appears to be TB-500, a peptide fragment of Thymosin Beta-4. Those substitutions matter when someone is trying to research what they just watched.

Does the science back this up?

Partially, and unevenly. The general principle that receptor desensitization and feedback loop disruption are real concerns with long-term peptide use is biologically sound. That's not controversial. But the specific cycling windows cited have almost no peer-reviewed backing for most of these compounds.

BPC-157 has the most preclinical data of any peptide on this list. Studies in rodents, including work by Sikiric et al. (2018, Current Pharmaceutical Design), show wound healing and gastroprotective effects. But human trial data is sparse, and no consensus cycling protocol exists in the clinical literature. MOTS-c is genuinely interesting as a mitochondrial-derived peptide, with research by Lee et al. (2015, Cell Metabolism) showing metabolic effects in mice, but human dosing and cycling windows are essentially unknown. GHK-Cu has skin and tissue repair research behind it, but the "12 months a year" recommendation is not drawn from any controlled study. NAD+ precursors have more human data than most on this list, and continuous use is not generally flagged as problematic in the literature, so that claim is at least defensible.

What did they get wrong (or right)?

The creator gets credit for the underlying reasoning. Saying you shouldn't run signaling compounds "in overdrive 365 days a year" reflects a real pharmacological concern: tachyphylaxis, receptor downregulation, and suppression of endogenous production are all legitimate risks worth communicating to an audience. That's better than the influencers who say to just run everything indefinitely.

What they got wrong is presenting specific numerical cycling windows as if they're clinically validated. They aren't. "Four weeks on, four weeks off" for MOTS-c is not a protocol that comes from a human trial. It comes from Reddit, and the creator actually names Reddit in the transcript, which is at least honest but also disqualifying as a source for health guidance. Presenting community consensus as safety-informed timelines is misleading. For compounds like SLU-PP-332, an ERR agonist being studied by Bhatt et al. (2023, Journal of Medicinal Chemistry) for metabolic disease, there is no human data at all. Giving a cycling schedule for it is not health guidance. It's speculation dressed as protocol.

What should you actually know?

If you're considering any of these compounds, the gap between preclinical animal data and human clinical evidence is enormous for most of them. BPC-157 and GHK-Cu have more research behind them than MOTS-c or SLU-PP-332, but even for BPC-157, no phase 2 or phase 3 human trials have been completed and published. NAD+ precursors like NMN and NR have the strongest human safety record of anything on this list, with studies including Yoshino et al. (2021, Science) showing metabolic effects in postmenopausal women at defined doses.

Cycling schedules for peptides exist because of plausible biology and community experience, not clinical trials. That doesn't mean they're useless, but it means they carry real uncertainty. These compounds are not FDA-approved for the uses described. Compounded peptides exist in a regulatory gray zone. Anyone dispensing or using them should understand that the absence of a documented adverse event in online communities is not the same as a demonstrated safety profile.